Skip to main content

Biomarkers for Traumatic Brain Injury / Search Inside This Book
Return to Search Inside This Book results

96 matches found for How People Learn Brain,Mind,Experience,and School Expanded Edition. in 5 Looking Ahead

Select a page to see where your word(s) or phrase(s) are located in the OpenBook. Excerpts from the chapter provide context.


At the bottom of page 47...
... This final chapter highlights overall messages and directions for potential future work on traumatic brain injury (TBI) biomarkers reported by workshop participants, as well as ongoing challenges to ...
At the bottom of page 47...
... Leslie Prichep, BrainScope Company, introduced the final discussion session. With many potential directions to pursue and limited resources, she said, identifying areas with the greatest potential for return on investment and added value to patients and families can help ... a course for the future. Referring to Figure 1-1 (see Chapter 1), she also reflected that although the dimensions of type, time after injury, and purpose of biomarkers are listed separately, in reality these areas overlap. Researchers and clinicians in TBI cannot look at any one area without ... them in the context of the other two. This fact reinforces the potential advances that will arise from combining information from multiple biomarkers and from integrating biomarker data with other clinical information to more optimally inform decision-making....
At the bottom of page 47...
... Based on the presentations and discussions, Prichep conducted an informal poll of workshop participants (in person and online) on which time points, contributions to care and research, and considerations for integration can have the most evidence for immediate impact ...
In the middle of page 48...
... Rank the time points at which biomarkers can currently play a significant role in TBI care and research: acute (≤ 72 hours); post-acute (> 72 hours and < 6 months); long term (> 6 months); and research....
In the middle of page 48...
... Rank the contributions that could currently be made by biomarkers to TBI care and research: diagnosis/classification; optimizing/targeting treatment; monitoring recovery; and research to fill gaps....
In the middle of page 48...
... What are the main considerations in integration of biomarkers into the current workflow? Food and Drug Administration (FDA) clearance/approval, ease of use, actionable result, or more research needed?...
At the bottom of page 48...
... Responses from in-person and remote attendees were collected using Survey Gizmo. After a short pause, during which approximately 80 responses were received, Prichep briefly ... question 1, respondents ranked the time points during which TBI biomarkers could currently have the greatest effect as acute, research, post-acute, and long term. Most of the biomarker data presented during the workshop addressed the acute period, she noted, and it is generally agreed that there is ... for the performance of TBI biomarkers over the longer term. This was reflected in the responses with the highest ranking for the acute period and the lowest ranking for the long-term period. The understanding and analysis of biomarker performance over the longer term represents an ongoing ...
At the bottom of page 48...
... that TBI biomarkers could currently play as being greatest for diagnosis/classification, optimizing/targeting treatment, research to fill gaps, and monitoring recovery....
At the bottom of page 48...
... into clinical workflows. The relative rankings in response to this question were close to one another, Prichep said, with actionable results and ease of use being the highest ranked, and FDA clearance and more research needed ranked a bit lower....
At the bottom of page 48...
... POTENTIAL NEXT STEPS AND OPPORTUNITIES IDENTIFIED BY PARTICIPANTS...
At the bottom of page 48...
... development of TBI biomarkers and their roles in TBI care and research. During the final sessions of the workshop, moderated by Prichep, participants expanded on a number of key points about the state of the science, roles that biomarkers currently play in the TBI landscape, their potential futures uses, ...
In the middle of page 49...
... future directions such as progress in techniques for analyzing information provided by multiple types of TBI biomarkers, incorporating feedback from expanded clinical use of biomarkers, evaluating the utility of biomarkers in expanded care settings and in additional types of patient populations, and ...
At the bottom of page 49...
... TBI care is already informed by biomarkers, including those obtained through neuroimaging, while FDA-cleared tests for blood and electrophysiological biomarkers are beginning to reach clinical practice. Several participants noted that it is becoming increasingly clear that ... TBI biomarkers are at the cusp of additional clinical applications for diagnosis and classification, prognostication, and monitoring of recovery. TBI is a complex multisystem phenomenon, a participant emphasized. There will likely never be a single biomarker that ... all the important dysfunction that occurs after injury; however, a multidimensional profile of TBI is emerging and may be very useful, not only for diagnosis and classification, but ultimately in informing treatment. The profiles of these TBI biomarkers have ... to help researchers understand laboratory and clinical TBI endophenotypes, and to aid in the management of TBI throughout the continuum of care and across the spectrum of injury. However, the lessons from incorporating troponin into cardiac care demonstrate the importance of conducting biological ... studies and understanding reference ranges, standardizing assays, and establishing laboratory turnaround time needs and expectations as part of the translation and implementation of biomarkers into practice....
At the bottom of page 49...
... There are a lot of opportunities in the biomarker tool kit, another participant commented, and there is a need for different types of tools. It will be important for clinicians and researchers to identify the problem that needs to be solved, ... the capabilities of the available biomarker tools, and identify the right ones to use, based on the indication and context of use. In addition to their applicability for clinical diagnosis and the continuum of care after a TBI, biomarkers such as blood-based glial ... (GFAP) can serve as potential pharmacodynamic response biomarkers for preclinical drug screening. Such efforts may aid in the enhanced assessment and development of TBI therapeutics....
In the middle of page 50...
... types of biomarker measures in multimodal analyses. For example, a participant noted that combining biomarkers based on electroencephalograms (EEGs) and blood biomarkers would provide two perspectives that have different timelines and that characterize different aspects of brain function and injury. ... and strategies raised during the workshop included the further development of analytic pipelines and standards, and the importance of further developing analytic techniques to integrate such diverse, multimodal information, as well as obtaining FDA clearance....
In the middle of page 50...
... Levels of Evidence and FDA Clearance...
At the bottom of page 50...
... Several participants emphasized the consideration of which biomarkers are ready for use now, in which settings and contexts, including which biomarkers can be measured using FDA-cleared assays and devices. As the informal poll reflected, more evidence is currently ... on the use of biomarkers in acute TBI care. But others noted potential limitations in the generalizability of studies and that more research is likely needed in certain populations (including in children and in older adults), as well as more fully understanding baseline ... values and the role of intra- and interindividual variation. For example, a participant highlighted how the current state of care for geriatric TBI reflects a crisis of ... in research. Without studies that represent this population, she said, older adults will continue to lack evidence-based TBI treatment and management guidelines. Another participant agreed with the need to study biomarker profiles in the full range of patients who experience TBI, noting ... it will be crucial to ensure gender and racial diversity in the ongoing research and care agenda....
At the bottom of page 50...
... The continued collection and analysis of biomarker profiles over time and how these profiles inform TBI prognostication over the longer term is an area that needs to be further explored and represents a potential future ... for the field. Several participants also reflected on issues of clarity and transparency when discussing TBI biomarker assays and results. Using the example of GFAP, discussions during the workshop raised the issue that not all assays measure the same GFAP structure (e.g., the ... isoform or breakdown product), in the same ways or at the same antibody concentration levels, or use the same cutoff values. To compare results and understand next steps, it is important to know the specific details of the targeted protein and assay parameters being used....
At the bottom of page 50...
... One participant commented that when using and interpreting biomarker tests, clinicians will want systems that are easy to use but will likely also want access to the data, not only to automated ...
In the middle of page 51...
..., a participant commented that algorithms were initially able to provide only categorical binary or ternary results. However, she continued, the score and the threshold for this measure are now provided, enabling a provider to review and decide the next care steps and to evaluate change over time. ... has shown that clinicians often use their judgment on how close the result score is to the threshold to inform their decision, and this offers more nuance than a binary yes or no outcome. Looking ahead, several participants agreed that feedback from the clinical use of biomarkers ... be important in helping to create and refine the next generation of measures....
In the middle of page 51...
... Adoption and Implementation of TBI Biomarkers into Clinical Practice...
At the bottom of page 51...
... A number of participants noted issues associated with the effective incorporation of biomarkers into clinical workflows, including economic and workforce considerations. Such implementation elements cannot be overlooked in the translation and adoption of biomarkers into clinical practice. For ... , a participant noted that incorporating biomarkers into practice in emergency department settings will require addressing the speed of results and effect on emergency department throughput, cost-effectiveness, and patient acceptance, as well as how results can be incorporated into patient ...
At the bottom of page 51...
... In the setting of longer-term TBI, a participant asked about combating challenges with insurance reimbursement and the ability to provide care to patients who depend on rehabilitation interventions to change their long-term recovery trajectories. To address this, ... participant suggested that clinicians will need to be armed with objective evidence and informational aids that make connections among biomarker results, rehabilitation interventions, and improved outcomes to be accepted by those who ... such cost and approval determinations....
At the bottom of page 51...
... In addition to documenting anticipated effects and returns on investment from incorporating further types of TBI biomarkers in various clinical settings, other participants highlighted the important ...
In the middle of page 52...
... guidelines and policies covering the use of TBI biomarker tests will be important aspects in this adoption and buy-in process....
In the middle of page 52...
... As described in prior chapters, several participants noted that current TBI classification into the categories of mild, moderate, and severe does a disservice to many patients. During the course of the workshop, a number of participants emphasized the opportunity for the TBI field ...
In the middle of page 52...
... Considering Future Questions and Directions...
In the middle of page 52...
... highlighted a variety of areas in which further study is needed—including further research in various patient populations, for different mechanisms and severities of injury, in different clinical settings and contexts of use, and in further biomarker discovery, validation, and multimodal analyses....
At the bottom of page 52...
... For patients and families experiencing TBI, a participant reiterated that much of the lived experience of TBI takes place outside of a hospital or clinic, often in ... home, workplace, or community. While biomarkers may be measured and incorporated into formal health records, other types of personnel, such as athletic trainers, emergency medical providers, and caregivers should have ... to tools and information as well. Building on the discussions of the potential use of biomarkers in prehospital settings, several participants commented that ... and development of TBI biomarkers in prehospital settings is an important area for further study, noting also that this area could draw on the ability of ...
At the bottom of page 52...
... information to inform loved ones caring for TBI patients is the next frontier, a participant emphasized. The ability to better provide patients and families with information about what can be done to support them in optimal recovery would be transformative. The question was raised whether ... , University of California, San Francisco, referred to a South American study that found the same outcomes from monitoring intracranial pressure and from physicians at the bedside conducting frequent neurological exams and imaging.1 This result reinforces...
In the middle of page 53...
... the importance of being a clinician and speaking with patients and families, first and foremost, he said. After the acute phase, an important role of TBI care is to have hands on the patient, reassure them, and educate them about their ... and anticipated recovery trajectory. The continued longitudinal study of biomarker information to better understand injury progression, risk of late complications, and predictive value in TBI remains important in this consultation process....
At the bottom of page 53...
... With such a heterogeneous population of TBI patients, adequately studying the full course of injury and recovery and measuring the right markers effectively remain important areas of development. During the course of the meeting, a number of participants noted ... populations in which biomarker performance after TBI injury and during recovery needs to be better understood, including geriatric TBI patients, people who have experienced multiple head injuries, and those with ... , or dementia. The ability to account for the potential confounding effect on biomarker results from situations such as preexisting head injury and coexisting medical conditions is important....
At the bottom of page 53...
... of biomarker assays with the data infrastructure world. One participant suggested the need to further build out data use agreements with academic and private partners and the need for additional efforts to design information systems to gather and synthesize relevant TBI biomarker information. ... that collate and synthesize the available information could also make this information more accessible to providers outside of major trauma centers. A patient should ...
At the bottom of page 53...
.... Future areas noted by participants included the continued expansion of biomarker discovery platforms within TBI consortia, as well as studying and validating potential “good” biomarkers, whose levels increase in positive states of recovery, compared to what most of the discussion covered, ... the use of non-hypothesis-based methods as a promising avenue to identify which fluid-based biomarkers are most informative for TBI diagnosis and prognosis and to determine pathological mechanisms to inform future therapeutics. In the field of electrophysiological biomarkers, tools such as EEG ... well established, give immediate results, and are sensitive to connectivity between brain regions and networks, another participant commented, although they are sensitive to factors that are difficult to control. Suggestions for future development ... advances in analytical technologies for furthering the understanding of the flow of information between regions of the brain, the use of techniques such as network analysis, and the continued incorpora-...
In the middle of page 54...
... tion of measures that complement EEG, such as heart rate variability, eye tracking, and clinical history....
At the bottom of page 54...
... Presentations and discussions over the course of the 1-day workshop brought together clinicians and TBI care providers, patient and family advocacy organizations, agency policy makers, industry partners, and others. Corinne Peek-Asa, University of California, San Diego, closed out ... workshop, thanking speakers and participants and noting that the sessions highlighted multiple ways in which biomarkers can play expanding roles in the assessment, care, and monitoring of traumatic brain injury in preclinical TBI research, and in informing clinical trials for new ... and interventions. This is an active area for the TBI field, although a number of challenges will need to be overcome to collectively push the frontiers ... the field forward and fully realize the promise of biomarkers in improving care for TBI patients and families....

A total of pages of uncorrected, machine-read text were searched in this chapter. Please note that the searchable text may be scanned, uncorrected text, and should be presumed inaccurate. Page images should be used as the authoritative version.